GPR39 activation inhibits AQP2 trafficking and alters cytoskeletal organization

G protein-coupled receptor 39 (GPR39) is an orphan receptor that is highly expressed in renal collecting duct principal cells. GPR39 activation in vivo leads to reduced urinary concentration capacity. In this study, we used mpkCCD cells, a model of principal cells in the collecting duct, to examine the cell biological effects of GPR39 activation. Pharmacological activation of GPR39 with the synthetic agonist cpd1324 impaired vasopressin-mediated aquaporin-2 (AQP2) apical trafficking and reduced total AQP2 expression following long-term treatment, consistent with its known in vivo role. These effects were absent in GPR39 knockout cells. In addition, GPR39 activation altered apical membrane morphology, disrupted the tight junction network, and reduced cortical F-actin expression, suggesting a shift toward a dedifferentiated phenotype. GPR39 activation also increased glycolytic ATP production while reducing mitochondrial ATP output without affecting proliferation. RNA-Seq analysis of acutely treated mpkCCD cells revealed upregulation of inflammatory and dedifferentiation-associated gene programs, including cytokines. These findings indicate that the role of GPR39 in principal cells goes beyond AQP2 regulation and imply that GPR39 functions as a negative regulator of epithelial differentiation, perhaps acting to coordinate metabolic and inflammatory responses to stress.<b>NEW & NOTEWORTHY</b> This study presents the first exploration of the cellular and molecular mechanisms underlying GPR39 activation in a physiologically relevant in vitro model of the renal collecting duct, mpkCCD cells. Our findings implicate GPR39 in the regulation of aquaporin-2 expression and trafficking, cytoskeletal organization, and cellular metabolism. In addition, RNA sequencing of GPR39-activated cells revealed transcriptomic changes related to immune signaling, stress response, and differentiation.